Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of 1H-NMR Spectroscopy and Gas Chromatography–Mass Spectrometry

Previous work demonstrated that serum metabolomics can distinguish pancreatic cancer from benign disease. However, in the clinic, non-pancreatic periampullary cancers are difficult to distinguish from pancreatic cancer. Therefore, to test the clinical utility of this technology, we determined whethe...

Повний опис

Бібліографічні деталі

Автори:	Yarrow J. McConnell, Farshad Farshidfar, Aalim M. Weljie, Karen A. Kopciuk, Elijah Dixon, Chad G. Ball, Francis R. Sutherland, Hans J. Vogel, Oliver F. Bathe
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2017-01-01
Серія:	Metabolites
Предмети:	biomarkers metabolomics pancreatic cancer periampullary adenocarcinoma
Онлайн доступ:	http://www.mdpi.com/2218-1989/7/1/3
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!